Log in using OpenID

Tuberculosis Drugs Market Trends Estimates High Demand By 2026

The Global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to witness a CAGR of 23.4% during the forecast period (2016 – 2024). Tuberculosis is a deadly infectious disease that affects the lungs.
Tuberculosis Drugs Market Value Projected to
Expand by 2018-2026
Global Tuberculosis Drugs Market, By Therapy Type (First Line Drugs Therapy,
Second Line Drugs Therapy, Combination Drugs Therapy), and Geography Insights, Opportunity Analysis, and Industry Forecast till 2024
The Global tuberculosis drugs market was valued at US$ 1,333.1 million in 2015 and is expected to
witness a CAGR of 23.4% during the forecast period (2016 – 2024). Tuberculosis is a deadly infectious
disease that affects the lungs. Among diseases, tuberculosis is the second largest cause of death
worldwide. Tuberculosis are broadly classified as latent tuberculosis and active tuberculosis. Globally
around 10% of latent infections develop into active tuberculosis. Infections that do not show any
symptoms are called latent tuberculosis. In 2015, the malady resulted in 1.8 million deaths and 10.4
million new reported cases. In 2015, in the U.S., there were 9,557 tuberculosis cases reported.
Based on the statistics of Center for Disease Control and Prevention, a 1.6% increase in the number of
tuberculosis cases was observed in 2015 as compared to those reported in 2014. Though there is an
increase in the number of tuberculosis cases, the incidence rate per 100,000 persons has been around
3.0 since 2013.
Market Dynamics
Asia and Africa are the largest markets for tuberculosis drugs, as these regions have the highest
prevalence of TB. There are many initiatives taken to control the TB increasing cases. The United
Nations’ Millennium Development Goals have framed various strategies to reduce TB prevalence and
death rates by 2015, which can be achieved by WHO’s Stop TB Strategy. According World Health
Organization, in 2006, 61% out of 2.5 million new smear positive cases with DOTS, and are all the
new smear cases on the year, and the treatment was successful in 85% cases. The estimated global
incidence rate of tuberculosis shown decline rate by 0.6% in 2005 and 2006. In 2006, the incidence rate
of tuberculosis became stable in the Europe and is declining gradually in the other WHO countries.
World Health Organization has an approximation that the occurrence of tuberculosis and death rates are
declining faster than the incidence rate.
Ask For Sample Copy Of This Business Research Report :
Detailed Segmentation:
•Global Tuberculosis Drugs Market, By Therapy Type:
•First Line Drugs Therapy
•Second Line Drugs Therapy
•Combination Drugs Therapy
With the significant increase in revenue of tuberculosis drugs market, over last decade, more than 10
chemical moiety have advanced into the clinical trial development pipeline, which include six new
chemical moiety significantly and specifically developed for tuberculosis. Though there are molecules
in clinical development phase, the global drug pipeline for tuberculosis is still not sufficient to address
the unmet needs of treatment. Many pharmaceutical companies have produced molecules that are under
clinical trials and the key challenges by any company to develop new product to treat tuberculosis and
effects the tuberculosis drugs market are the needs for drugs in combination therapy, new trial
strategies, studies on pediatric TB drugs, population and increased clinical trial capacity and clear
regulatory guidelines.
High funding for research and development and clinical trials drugs to boost the tuberculosis
drugs market
There was around US$ 6.6 billion revenue accessible for tuberculosis care and prevention in many of
the low and middle-income countries in 2016, out of which 84% was from domestic sources. However,
national tuberculosis program (NTPs) in low income countries linger to depend on international donors
or foreign healthcare agencies to fund them approximately 90%. Investments in low income countries
and middle income countries declined by US$ 2 billion to US$ 8.3 billion, which was needed in 2016.
There were many enhancements needed in overall healthcare financing to curb new tuberculosis cases
proportionally boosting tuberculosis drugs market. Government expenditures on healthcare in specific
to tuberculosis in 2014 were less than the World Health Organization set a benchmark of at least 6% of
gross domestic product in around 150 countries. Private expenditures surpassed 45% of total healthcare
expenditures in tuberculosis in 46 countries, which also includes 11 of the 30 high tuberculosis burden
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
ravikiran303   documents Email
Health and Medicine
File Size
379 KB
Report inappropriate content